retatrutide clinical data retatrutide Results: 28.3% Weight Loss The data just dropped —

These compounds interact with three key hormone receptors involved in metabolic signaling: GLP-1 receptors GIP receptors Glucagon receptors Because of this three-pathway approach, some researchers informally refer to these compounds as GLP-3 drugs or Triple-G agonists

The results were remarkable

Together, these medications provide robust HbA1c reduction with minimal hypoglycaemia risk, making them particularly valuable for patients requiring treatment intensification beyond metformin-based therapy

Quality assessment Two RCTs were rated as high risk of bias due to inadequate reporting of randomization procedures (Figure 2)

Most patients begin with a 0.25 mg dose in week one, then progress through 0.5 mg, 1.0 mg, 1.7 mg, and up to 2.4 mg maintenance depending on tolerability and clinical response